This work is licensed under the Creative Commons Attribution 4.0 International License.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72:7–33.SiegelRLMillerKDFuchsHEJemalACancer statistics, 2022CA Cancer J Clin.202272733Search in Google Scholar
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016; 25:16–27.TorreLASiegelRLWardEMJemalAGlobal cancer incidence and mortality rates and trends – an updateCancer Epidemiol Biomarkers Prev.2016251627Search in Google Scholar
Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018; 37:1–15.TangLWeiFWuYHeYShiLXiongFRole of metabolism in cancer cell radioresistance and radiosensitization methodsJ Exp Clin Cancer Res.201837115Search in Google Scholar
Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer/Radiothér. 2014; 18:391–5.RekersNHTroostEGZegersCMGermeraadWTDuboisLJLambinPStereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectivesCancer/Radiothér.2014183915Search in Google Scholar
Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018; 17:1–11.ZhongYDuYYangXMoYFanCXiongFCircular RNAs function as ceRNAs to regulate and control human cancer progressionMol Cancer.201817111Search in Google Scholar
Jones HA, Hahn SM, Bernhard E, McKenna WG. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001; 11:328–337.JonesHAHahnSMBernhardEMcKennaWGRas inhibitors and radiation therapySemin Radiat Oncol.200111328337Search in Google Scholar
Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol. 2006; 16:59–64.ChinnaiyanPAllenGWHarariPMRadiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and RasSemin Radiat Oncol.2006165964Search in Google Scholar
Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010; 3:1–11.FréminCMelocheSFrom basic research to clinical development of MEK1/2 inhibitors for cancer therapyJ Hematol Oncol.20103111Search in Google Scholar
Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007; 1773:1213–26.ShaulYDSegerRThe MEK/ERK cascade: from signaling specificity to diverse functionsBiochim Biophys Acta.20071773121326Search in Google Scholar
Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, et al. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res. 2009; 15:3050–7.ChungEJBrownAPAsanoHMandlerMBurganWECarterDIn vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinaseClin Cancer Res.20091530507Search in Google Scholar
Xia Y, Wang Y, Xue L, Yu D. Radiosensitizing effect of MEK specific inhibitor U0126 on A549 cells and its mechanism. J Radiat Res Radiat Proc. 2014; 32:10–5.XiaYWangYXueLYuDRadiosensitizing effect of MEK specific inhibitor U0126 on A549 cells and its mechanismJ Radiat Res Radiat Proc.201432105Search in Google Scholar
Estrada-Bernal A, Chatterjee M, Haque SJ, Yang L, Morgan MA, Kotian S, et al. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Cell Cycle. 2015; 14:3713–24.Estrada-BernalAChatterjeeMHaqueSJYangLMorganMAKotianSMEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathwaysCell Cycle.201514371324Search in Google Scholar
Zhu Z, Tian H. Radiosensitizing effects of novel benzothiadiazole derivatives on KRAS-mutant non-small cell lung cancers. Int J Biomed Eng. 2018; 41:138–47.ZhuZTianHRadiosensitizing effects of novel benzothiadiazole derivatives on KRAS-mutant non-small cell lung cancersInt J Biomed Eng.20184113847Search in Google Scholar
Cheng Y, Wang X, Xia X, Zhang W, Tian H. A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer. Int J Cancer. 2019; 145:586–96.ChengYWangXXiaXZhangWTianHA benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancerInt J Cancer.201914558696Search in Google Scholar
Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, et al. Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci. 2017; 18:367.LiuGPeiFYangFLiLAminADLiuSRole of autophagy and apoptosis in non-small-cell lung cancerInt J Mol Sci.201718367Search in Google Scholar
Neal RD, Hamilton W, Rogers TK. Lung cancer. BMJ. 2014; 349:g6560. doi: 10.1136/bmj.g6560NealRDHamiltonWRogersTKLung cancerBMJ.2014349g656010.1136/bmj.g6560Open DOISearch in Google Scholar
Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao M-S. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer. 2006; 8:30–8.Aviel-RonenSBlackhallFHShepherdFATsaoM-SK-ras mutations in non-small-cell lung carcinoma: a reviewClin Lung Cancer.20068308Search in Google Scholar
Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non–small-cell lung cancer. J Clin Oncol. 1999; 17:668–75.GrazianoSLGambleGPNewmanNBAbbottLZRooneyMMookherjeeSPrognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non–small-cell lung cancerJ Clin Oncol.19991766875Search in Google Scholar
Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Inv Drug. 2018; 27:17–30.KimCGiacconeGMEK inhibitors under development for treatment of non-small-cell lung cancerExpert Opin Inv Drug.2018271730Search in Google Scholar
Jones GG, Del Río IB, Sari S, Sekerim A, Young LC, Hartig N, et al. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nat Commun. 2019; 10:1–16.JonesGGDel RíoIBSariSSekerimAYoungLCHartigNSHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancersNat Commun.201910116Search in Google Scholar
Lu L, Jiang M, Zhu C, He J, Fan S. Amelioration of whole abdominal irradiation-induced intestinal injury in mice with 3, 3′-Diindolylmethane (DIM). Free Radical Biol Med. 2019; 130:244–55.LuLJiangMZhuCHeJFanSAmelioration of whole abdominal irradiation-induced intestinal injury in mice with 3, 3′-Diindolylmethane (DIM)Free Radical Biol Med.201913024455Search in Google Scholar